Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). Homo sapiens

This study was included as part of a GWAS consortium. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) was initiated as a large, randomized, two-arm trial with the aim of determining the effectiveness of screening to reduce cancer mortality. Ten centers enrolled 154,934 participants, including males and females, aged between 55 and 74 years. 93% of participants assigned to the screening arm provided a baseline blood sample; 65% of those in the observational arm provided a buccal cell sample using the "swish-and-spit" protocol. PLCO samples for this project consisted of colorectal cancer cases, from both arms of the trial which had not been previously genotyped.